Lancet HIV Publishes Early Study Results for Long-Acting Dual-Antibody HIV Regimen

TaiMed Biologics announced the publication of Phase 1b/2a clinical study results for its long-acting dual-antibody HIV maintenance regimen, TMB-365/TMB-380, in The Lancet HIV. The study evaluated the safety, pharmacokinetics, and antiviral activity in HIV-positive individuals who had achieved viral suppression. These findings are crucial for the continued clinical development of this novel dual-antibody approach, potentially offering a new maintenance option.